Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, JS, Majer, IM, Pietrantonio, F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00352-3. PMID:40812325. IF:35.900(Q1/1D).

Herrera, IC, Fabregó, IE, Cols, LC, Lladó, MC, Vidal, AG, Martín, LF, Mariscal, IE, Arango, SMR, Metrallé, SCS, Alcañiz, AG. Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis. VIRCHOWS ARCHIV. 2025; 487DOI:. PMID:. IF:3.100(Q2/3D).

Riedell, PA, Kwon, M, Flinn, IW, Dickinson, MJ, Solano, C, Jaeger, U, Briones, J, Kato, K, Fleming, S, Bachy, E, Rambaldi, A, Shune, LO, Shah, NN, Blaise, D, Frigault, MJ, Ramakrishnan, A, Yang, A, Pearson, D, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Jabbour, E, Recher, C, O'Nions, J, Aldoss, I, Pierola, A, Allred, A, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Curtis, M, Daskalakis, N, Della Porta, MG, Döhner, H, D'Souza, A, Dugan, JP, Reyner, JE, Exum, M, Fathi, AT, Fedele, PL, Ferrante, L, Gaj, S, Garciaz, S, Garrido, A, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Kwon, MC, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Martinelli, G, Giles, DM, Murphy, J, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Rangaraju, S, Röllig, C, Salamero, O, Sanga, M, Sauer, T, Searle, E, Tovar, N, Tucker, T, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Wei, A. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).